 This study will evaluate the optimal dose of tofacitinib needed to achieve low disease activity LDA or clinical remission as measured by the CDAI score. Once LDA or clinical remission has been achieved, the structural benefit in reducing erosions, synovitis and bone edema as measured by low field MRI will be determined at the same time period by the use of the OMERACTRAMRIS scoring system 